Top Growth Stocks for 2026: Targeting Consistent 15%+ Revenue Growth
As expectations for global economic growth moderate, identifying high-quality stocks with sustained momentum has become a critical task for investors. According to research firm CFRA, a key criterion for identifying stocks with genuine long-term potential is a demonstrated track record of at least 15% annual revenue growth in each of the past three years. This stringent benchmark helps investors cut through market noise to find companies with fundamental strength.
Why Consistent 15% Revenue Growth Matters
Sustained high revenue growth is a direct reflection of a company’s competitive edge. Amid increased market volatility in 2025, firms capable of maintaining this level of growth have demonstrated remarkable business resilience and adaptability. With the Federal Reserve expected to continue cutting interest rates, this class of high-quality growth stocks is well-positioned to lead the market.
Here are some of CFRA’s top picks for 2026 that meet this consistent growth standard and are favored by analysts:
- Nvidia Corp. (NVDA)
This semiconductor giant has not only met the three-year growth requirement but also posted spectacular recent results: fiscal third-quarter revenue surged 62% year-over-year, with net income up 65%. Analyst Angelo Zino emphasizes that Nvidia’s positioning in edge computing, global market expansion, and software services will drive continued growth, projecting a 60% revenue increase for fiscal 2026. CFRA has a “Strong Buy” rating and a $270 price target on NVDA.
- Broadcom Inc. (AVGO)
As a diversified semiconductor supplier, Broadcom reported 43% revenue growth in fiscal 2024 and maintained a 22% growth rate in the most recent quarter, comfortably exceeding the 15% threshold. Its AI-related revenue skyrocketed 63%, becoming a primary growth driver. Analysts expect the company to continue benefiting from the AI infrastructure investment boom, projecting 29% revenue growth for fiscal 2026. CFRA rates AVGO a “Buy” with a $380 price target.
- Eli Lilly & Co. (LLY)
This pharmaceutical company has achieved exceptional growth through its breakthrough products in diabetes and weight loss. Third-quarter total revenue grew 54%, with sales of weight-loss drug Mounjaro soaring 109% and Zepbound surging 185%. Having met the three-year growth criteria, the company is projected to maintain 15.8% revenue growth in fiscal 2026. CFRA rates LLY a “Buy” with a $1,101 price target.
- Palantir Technologies Inc. (PLTR)
As a leader in big data analytics, Palantir reported 63% revenue growth in the third quarter, with U.S. commercial revenue exploding by 121%. The company consistently surpasses the 15% growth benchmark, highlighting its strong momentum in AI and big data. Analysts project 47% revenue growth in 2026. CFRA maintains a “Buy” rating and a $231 price target on PLTR.
Investment Outlook
In the current complex economic environment, employing rigorous financial screening criteria is more important than ever. The requirement of three consecutive years of 15% revenue growth helps investors identify companies with durable business models, distinguishing them from those reliant on short-term market trends. A portfolio built upon this disciplined standard offers a more reliable framework for investors positioning their holdings for 2026.
Financial Reports
Growth Stocks
Pharmaceutical
Technology
